Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

A Novel 3Rs Microphysiological Alternative Platform for Parkinson’s Disease

Project description

Engineering a brain-on-a-chip platform to study Parkinson’s disease

The incidence of Parkinson’s disease (PD) has significantly increased over the past decades. Meanwhile, researchers are challenged to discover effective therapeutics, since results from animal testing often fail to work well on humans. To address this, the ERC-funded ReMAP-PD project aims to develop a human-based testing platform that better reproduces PD molecular hallmarks. This novel brain-on-a-chip platform uses living brain cells to replicate aspects of PD in the laboratory, providing an ethical and affordable way to study the disease and screen potential treatments reducing animal experimentation. To demonstrate the platform’s scientific robustness, ReMAP-PD will carry out performance metric analysis using a well-characterised panel of drug compounds.

Objective

Parkinson's disease (PD), a highly incapacitating neurodegenerative condition of complex and multifactorial origins, remains incurable. As PD cases have skyrocketed by circa 160% since 1990, the burden on society grows heavier. The lack of reliable systems to test new therapeutics, allied with the limitations of current animal gold standard models, have eluded the development of safe and efficacious molecules to fight PD.
ReMAP-PD aims at validating a novel 3Rs Microphysiological Alternative Platform for testing new therapeutics against Parkinson’s Disease based on a New Approach Methodology (NAM): a next-generation, human-based cellular disease model - fully aligning with the 3Rs principle of replacing, reducing and refining animal testing. Building on a novel microphysiological system, this PoC will deliver a scientifically robust and ethically compliant brain-on-chip platform that emulates key pathological features of PD. By validating this new platform for major in vivo PD cellular and molecular hallmarks, ReMAP-PD presents advantages over other NAMs for PD in terms of: ethical constrains related to cell source and accessibility; reagent costs; technical skills and standardization and user friendliness. With no current robust alternative to test new compounds against PD, ReMAP-PD will not only enhance NAMs translational value but also support a paradigm-shift in disease modelling, accelerating innovation while reducing reliance on animal experimentation.
To unlock ReMAP-PD's innovation potential, we plan to conduct performance metric analysis using a well-characterized panel of drug compounds. Positive outcomes will support EU regulatory submission and attract stakeholder interest, while paving the way for ReMAP-PD IPR protection.

Fields of science (EuroSciVoc)

This project has not yet been classified with EuroSciVoc.
Be the first one to suggest relevant scientific fields and help us improve our classification service

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2025-POC

See all projects funded under this call

Host institution

FACULDADE DE CIENCIAS E TECNOLOGIADA UNIVERSIDADE NOVA DE LISBOA
Net EU contribution
€ 150 000,00
Address
QUINTA DA TORRE
2829 516 Caparica
Portugal
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data

Beneficiaries (1)